1. Home
  2. ARVN vs PFL Comparison

ARVN vs PFL Comparison

Compare ARVN & PFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ARVN
  • PFL
  • Stock Information
  • Founded
  • ARVN 2015
  • PFL 2003
  • Country
  • ARVN United States
  • PFL United States
  • Employees
  • ARVN N/A
  • PFL N/A
  • Industry
  • ARVN Biotechnology: Pharmaceutical Preparations
  • PFL Finance Companies
  • Sector
  • ARVN Health Care
  • PFL Finance
  • Exchange
  • ARVN Nasdaq
  • PFL Nasdaq
  • Market Cap
  • ARVN 456.2M
  • PFL 375.4M
  • IPO Year
  • ARVN 2018
  • PFL N/A
  • Fundamental
  • Price
  • ARVN $7.77
  • PFL $8.35
  • Analyst Decision
  • ARVN Buy
  • PFL
  • Analyst Count
  • ARVN 21
  • PFL 0
  • Target Price
  • ARVN $20.53
  • PFL N/A
  • AVG Volume (30 Days)
  • ARVN 2.1M
  • PFL 113.7K
  • Earning Date
  • ARVN 07-29-2025
  • PFL 01-01-0001
  • Dividend Yield
  • ARVN N/A
  • PFL 11.53%
  • EPS Growth
  • ARVN N/A
  • PFL N/A
  • EPS
  • ARVN N/A
  • PFL N/A
  • Revenue
  • ARVN $426,900,000.00
  • PFL N/A
  • Revenue This Year
  • ARVN $4.26
  • PFL N/A
  • Revenue Next Year
  • ARVN N/A
  • PFL N/A
  • P/E Ratio
  • ARVN N/A
  • PFL N/A
  • Revenue Growth
  • ARVN 498.74
  • PFL N/A
  • 52 Week Low
  • ARVN $5.90
  • PFL $6.98
  • 52 Week High
  • ARVN $34.11
  • PFL $8.62
  • Technical
  • Relative Strength Index (RSI)
  • ARVN 50.16
  • PFL 56.43
  • Support Level
  • ARVN $7.09
  • PFL $8.30
  • Resistance Level
  • ARVN $7.89
  • PFL $8.35
  • Average True Range (ATR)
  • ARVN 0.35
  • PFL 0.04
  • MACD
  • ARVN 0.00
  • PFL 0.00
  • Stochastic Oscillator
  • ARVN 38.14
  • PFL 76.92

About ARVN Arvinas Inc.

Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.

About PFL PIMCO Income Strategy Fund Shares of Beneficial Interest

PIMCO Income Strategy Fund is a United States-based closed-end management investment company. The fund's investment objective is to seek high current income, consistent with the preservation of capital. It seeks to achieve its objectives by investing in a diversified portfolio of floating and fixed-rate debt instruments.

Share on Social Networks: